Pharma BD Deal Intelligence
A $1.265B AstraZeneca acquisition of TeneoTwo that turned a Phase 1 CD19xCD3 bispecific into two Phase 3 pivotal trials within two years. Early clinical data showed 96% overall response and 85% complete response in follicular lymphoma, positioning surovatamig as a potential first-in-class late-stage asset.
AstraZeneca to acquire TeneoTwo and T-cell engager TNB-486 for $100M upfront plus up to $1.17B milestones.
AstraZeneca acquired TeneoTwo with lead asset TNB-486 for $100M upfront and up to $1.165B in milestones.
AstraZeneca to acquire TeneoTwo in deal worth up to $1.26 billion for clinical T-cell engager.
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
AstraZeneca acquired TeneoTwo in October 2022 (closed 17 Oct 2022) for $100M upfront plus up to $1.165B in milestones (total up to ~$1.265B), gaining the Phase 1 CD19xCD3 bispecific T-cell engager TNB-486 for relapsed/refractory B-cell malignancies. Post-close the asset has advanced markedly: it received the INN surovatamig (AZD0486) and AstraZeneca moved it directly from Phase 1 into two Phase 3 pivotal programs. SOUNDTRACK-F1 (NCT06549595, Phase III, recruiting, started Aug 2024) tests surovatamig plus rituximab versus chemoimmunotherapy plus rituximab in previously untreated follicular lymphoma; a second Phase 3 (SOUNDTRACK-D2) evaluates surovatamig with R-mini-CHOP in large B-cell lymphoma. Phase 1 follicular-lymphoma data (ASH 2024) showed a 96% overall response rate and 85% complete response at doses >=2.4 mg with predominantly low-grade cytokine release syndrome, and R/R DLBCL data (ASCO/ASH 2025) showed high MRD-negative complete responses including after prior CD20 TCE and CD19 CAR-T. The deal thesis has strengthened: AstraZeneca's bispecific bet is now a late-stage, potentially first-in-class CD19xCD3 program in B-cell lymphoma.
TNB-486 is a CD19xCD3 T-cell engaging bispecific antibody for B-cell NHL, entering a rapidly densifying bispecific/CAR-T market. CD20xCD3 bispecific T-cell engagers (dominant MOA class): glofitamab (Columvi, Roche) received FDA accelerated approval June 2023 for R/R DLBCL post-2L; epcoritamab (Epkinly, AbbVie/Genmab) received FDA accelerated approval May 2023 for R/R DLBCL post-2L, with follicular lymphoma indication added 2024; mosunetuzumab (Lunsumio, Roche) is approved for R/R follicular lymphoma. AbbVie reported Epkinly 2023 net revenues of approximately $96M in its launch year. CD19xCD3 bispecific (direct MOA competitors to TNB-486): odronextamab (Regeneron) has a Phase 2/3 program in FL and DLBCL with FDA approval anticipated; blinatumomab (Blincyto, Amgen) is CD19xCD3 but approved in B-ALL, not NHL. Anti-CD19 CAR-T: axicabtagene ciloleucel (Yescarta, Gilead/Kite, 2023 Gilead sales ~$1.5B), tisagenlecleucel (Kymriah, Novartis), and lisocabtagene maraleucel (Breyanzi, BMS) are approved for R/R LBCL after 2L; Yescarta and Breyanzi have second-line LBCL approvals (2022). Anti-CD19 ADC: loncastuximab tesirine (Zynlonta, ADC Therapeutics) is approved for R/R DLBCL after 2L. Anti-CD79b ADC: polatuzumab vedotin (Polivy, Roche) in frontline DLBCL. TNB-486 must differentiate on safety (CRS profile) or fixed-duration dosing to carve out share from established CD20 bispecifics.
AstraZeneca acquired TeneoTwo and lead bispecific TNB-486 (CD19xCD3) for hematologic malignancies.
AstraZeneca advanced the acquired asset (now INN surovatamig, AZD0486) directly from Phase 1 into the Phase 3 SOUNDTRACK-F1 trial (NCT06549595): surovatamig + rituximab vs chemo + rituximab in previously untreated follicular lymphoma.
Phase 1 follicular-lymphoma data for AZD0486 reported at ASH 2024 showed a 96% overall response rate and 85% complete response at doses >=2.4 mg, with predominantly low-grade cytokine release syndrome.
TNB-486 in clinical development for B-cell malignancies. Acquisition-style deal.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / TeneoTwo Inc. (this deal) | 2022 | $1.3B | 62 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2022 deals · AstraZeneca PLC deals · Oncology deals